Epigenetics Market by Product, Technique, Methods, Application, End User

List of Tables

[190 Pages Report] The Epigenetics Market size was estimated at USD 3.71 billion in 2023 and expected to reach USD 4.10 billion in 2024, at a CAGR 10.82% to reach USD 7.63 billion by 2030.

Epigenetics refers to the analysis of heritable phenotype modifications that do not involve alterations in the DNA sequence. It examines the chemical modifications that occur on DNA and histone proteins, which can affect gene expression without changing the underlying genetic code. These epigenetic changes can be influenced by several factors, including age, environment, and disease state, and they are reversible mechanisms passed down to subsequent generations. Epigenetics provides an additional layer of complexity to the regulation of gene expression, and it has significant implications for our understanding of genetics, development, and inheritance. Applications of epigenetics span from biomedical research to therapeutic interventions. In research, epigenetics offers insights into developmental biology and the etiology of diseases. Clinically, it has implications in cancer treatment, metabolic disorders, and personalized medicine. The primary end-users include academic & research institutes, pharmaceutical & biotech companies, and diagnostic centers. The need for epigenetics is increasing due to substantial growth in the prevalence of chronic and genetic disorders worldwide, favorable governmental initiatives and investments in drug discovery and development, and a growing inclination toward personalized medicines. However, the market faces certain challenges, including the high cost of developing epigenetics technologies, lack of awareness, and limited application of epigenetics, hindering the adoption of epigenetics. Ongoing research and development activities for the advancement of epigenetics and expanding the application of epigenetics in non-oncology fields present potential opportunities for the development of epigenetics.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.71 billion
Estimated Year [2024]	USD 4.10 billion
Forecast Year [2030]	USD 7.63 billion
CAGR (%)	10.82%

Product: Increasing usage of reagents & kits for epigenetic research

Enzymes play a pivotal role in epigenetic research, as they are responsible for adding or removing epigenetic markers such as methyl groups on DNA or histones. DNA-modifying enzymes, such as DNA methyltransferases (DNMTs) and TET enzymes, are crucial tools in epigenetic modification, widely used in research to study DNA methylation and hydroxymethylation patterns. Protein-modifying enzymes such as histone acetyltransferases (HATs), deacetylases (HDACs), methyltransferases, and demethylases alter histone proteins, influencing chromatin structure and gene expression. The tools necessary for epigenetic research, such as DNA sequencers, PCR amplifiers, sonicators for chromatin shearing, and advanced imaging systems, are fundamental to elucidating epigenetic modifications. These instruments, paired with essential accessories such as microplates, pipettes, and software, facilitate the precise analysis of epigenetic phenomena. Reagents and kits tailored for epigenetic research, which include bisulfite conversion kits or chromatin immunoprecipitation kits, serve to streamline and standardize processes. 5-hmC & 5-mC analysis kits simplify detecting and quantifying DNA methylation and hydroxymethylation. Validated antibodies against epigenetic markers such as methylated cytosine or various histone modifications are indispensable for techniques such as western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). Bisulfite conversion kits convert unmethylated cytosine residues to uracil, which enables the discrimination of methylated from unmethylated DNA via sequencing or PCR, serving as a cornerstone method in DNA methylation studies. ChIP-seq kits streamline the process of performing chromatin immunoprecipitation followed by sequencing. Unmodified and post-translationally modified core histone proteins and their variants are utilized for in vitro studies of chromatin remodeling and to understand how specific modifications influence gene expression. Whole genome amplification kits facilitate the amplification of nanogram quantities of DNA to microgram levels, which is essential for epigenetic analysis when starting material is limited, such as in single-cell studies. Epigenetics services include DNA methylation profiling, histone modification mapping, and chromatin accessibility assays. These specialized services leverage classic techniques, such as bisulfite sequencing, and modern high-throughput methods, such as next-generation sequencing, to support researchers in epigenetic data acquisition and interpretation. Epigenetics research yields large datasets that necessitate sophisticated bioinformatics tools for analysis. Software solutions provide data processing, visualization, and integration platforms, enabling the decoding of complex epigenetic networks. Services are increasingly becoming preferred for research entities lacking in-house capabilities or those looking for highly specialized expertise. Conversely, the software serves a complementary role, growing in importance as the volume and complexity of data escalate.

Technique: Expanding adoption of next-generation sequencing for genome-wide methylation profiling

Mass spectrometry is an analytical method that estimates the mass-to-charge ratio of ions. It is used in epigenetic studies to analyze DNA and histone changes, such as methylation and acetylation. The method is very precise, allowing for the detection of even small changes in epigenetic marks. Researchers may prefer mass spectrometry when they require high specificity and sensitivity or deal with complex mixtures. Next-generation sequencing (NGS) is a powerful method that allows for high-throughput sequencing of DNA and RNA, which is critical for understanding genetic and epigenetic patterns across the genome. NGS can be used for epigenetic applications such as genome-wide methylation profiling, chromatin immunoprecipitation sequencing (ChIP-seq), and RNA sequencing (RNA-seq) to study epigenetic changes at the transcriptional level. NGS is preferred when comprehensive, genome-wide analysis is required or while examining the effects of epigenetic changes on gene expression. Quantitative polymerase chain reaction (qPCR)and polymerase chain reaction (PCR) are techniques used to amplify and quantify specific DNA sequences. In epigenetics, these methods can quantify the methylation status of particular genes or measure gene expression changes resulting from epigenetic modification. PCR and qPCR are used by researchers that are interested in targeted analysis of specific DNA or RNA fragments rather than a broad, high-throughput approach. Sonication is a physical shearing process that uses sound energy to break nucleic acids and proteins into smaller fragments. It is often used in epigenetics during the preparation of samples for methods such as ChIP-seq, where chromatin must be sheared before immunoprecipitation can occur. Sonication is selected when uniform shearing of DNA is necessary, particularly in preparation for sequencing studies. Moreover, when choosing among these epigenetic analysis techniques, researchers consider the nature of their sample, the resolution needed, and the specificity and breadth of data they require. Mass spectrometry offers high specificity, making it ideal for detecting novel or small changes. NGS presents comprehensive and high-throughput capabilities for whole-genome analysis.

Methods: Rising utilization of DNA methylation for X-chromosome inactivation

DNA methylation is an epigenetic modification technique that leads to the repression of gene expression when located in gene promoters. It plays a critical role in diverse biological processes such as embryonic development, X-chromosome inactivation, and suppression of repetitive elements. DNA methylation analysis is preferred when studying early developmental stages and diseases that involve imprinting or X-chromosome inactivation. Techniques utilized for analyzing DNA methylation patterns include bisulfite sequencing, methylation-specific PCR (MSP), and array-based methods. Histone modifications occur on the histone proteins around which DNA is wound. The addition or reduction of chemical groups such as methyl, acetyl, phosphate, and ubiquitin to various amino acids on histones can affect chromatin structure and gene activity. Acetylation, for instance, is generally associated with transcriptional activation, while methylation can activate or suppress gene expression, relying on the specific amino acid and the number of methyl groups added. Research in gene regulation, chromatin dynamics, and transcriptional response to environmental stimuli can favor histone modification studies as it includes chromatin immunoprecipitation (ChIP) followed by sequencing (ChIP-seq), mass spectrometry-based methods and specific antibodies that recognize various histone modifications. DNA methylation and histone modifications are paramount for understanding the complex regulatory networks that drive gene expression. DNA methylation analyses are indispensable in certain contexts, such as developmental biology and disease studies where stable, long-term gene silencing is crucial. In contrast, histone modification analyses offer a dynamic view of chromatin and transcriptional changes. They are particularly beneficial for investigating rapid gene expression changes and the effects of environmental factors on chromatin structure.

Application: Increasing application of epigenetic tools in oncology

Cardiovascular diseases (CVDs) are a major area of focus for epigenetic research due to the increasing prevalence of heart-related health issues globally. Epigenetic tools, including DNA methylation, histone modification, and non-coding RNA expression, are believed to influence the development and progression of CVDs. Studies aimed at understanding these modifications could lead to identifying potential biomarkers for early detection and targeted therapies. Developmental biology is a critical application for epigenetic research, illuminating how epigenetic changes govern development processes from embryogenesis to adulthood. Researchers in this field are particularly interested in the way epigenetic profiles change during development, and they can result in developmental disorders when altered. In immunology, epigenetics applies to understanding the regulation of immune response and the potential to treat autoimmune diseases, allergies, and inflammatory conditions. The application segment relies heavily on understanding the interaction between epigenetic processes and immune cell differentiation. The need is propelled by the need for new therapeutic methods that modify immune system behavior without the adverse effects associated with current treatments. Epigenetic research in metabolic diseases targets conditions such as obesity, diabetes, and other metabolic syndromes. Epigenetics is used to decipher the gene-environment interactions contributing to such diseases. This arena provides fruitful ground for biomarker discovery and epigenetic drug development aimed at resetting metabolic profiles. Oncology is the most prominent application of epigenetics, given the role of epigenetic modifications in cancer development. Epigenetic drugs targeting DNA methylation and histone modification enzymes are already in use and are being studied extensively for various types of cancers. The need for epigenetic oncology approaches is immense, driven by the need for precision medicine and the high burden of cancer worldwide. Oncology, as a prominent segment, has witnessed significant investment and research due to the high impact of cancer-related deaths. It has steadily resulted in various approved epigenetic drugs and a robust pipeline of therapies.

End-User: Growing need for epigenetic tools from academic & research institutes

Academic and research institutes serve as primary grounds for basic research and discovery in epigenetics. These institutions strongly need advanced research tools such as next-generation sequencing (NGS), bioinformatics platforms, and epigenetic kits and reagents. The focus here is largely on understanding the mechanisms and implications of epigenetic changes rather than immediate commercial applications. Contract research organizations (CROs) operate as third-party service providers for various biotechnology, pharmaceutical, and medical device companies. They perform various services, from early-stage research to clinical trials and post-market support. In epigenetics, CROs need cutting-edge technologies that offer high-throughput capabilities and reliable validation services for drug discovery and development projects. CROs prefer robust, scalable solutions aligned with the pharmaceutical industry's stringent regulatory standards. Pharmaceutical and biotechnology companies are involved in developing and commercializing new drugs and treatments and an increasing number of these companies are being influenced by epigenetic insights. These companies require comprehensive epigenetic platforms that can streamline drug discovery, biomarker development, and therapeutic monitoring. The preference for pharma and biotech is for integrated solutions that deliver speed to market, efficacy, and safety.

Regional Insights

The epigenetics market in North America has exhibited substantial growth, primarily driven by the United States, attributed to heavy investments in research and development, the robust presence of pharmaceutical and biotechnology companies, and a high incidence rate of chronic diseases such as cancer. In South America, the adoption of epigenetics is in the nascent stage and has a potential for development due to the increasing prevalence of genetic disorders and cancers, and Brazil supports the development of epigenetics with an evolving healthcare sector and growing public awareness about advanced treatments. The APAC region is undergoing a rapid transition in the epigenetics sector due to emerging economies such as China, Japan, and India. China has witnessed a surge in patent filings, indicating strong governmental and private interest in epigenetics. The Japanese government encourages precision medicine, resulting in increased funding for epigenetic research programs. India's participation in epigenetic research is expanding, with an increasing number of collaborations and studies. Europe's epigenetics market is robust, led by countries such as Germany, the UK, and France. Extensive research activities, well-established healthcare systems, and growing investments from the private and public sectors propel the regional development. Additionally, active collaborations between key players and academic institutions support the development of advanced epigenetic therapies. The Middle East region is experiencing gradual progress in epigenetics due to the rising prevalence of conditions such as cancer and the expansion of healthcare infrastructure. The interest in personalized medicine is steadily gaining traction, influencing purchasing patterns. In Africa, the development of epigenetics is in the early stages, with limited research facilities. However, there is potential for expansion with increasing international collaboration in healthcare research.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Epigenetics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Epigenetics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Epigenetics Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Active Motif, Inc., Agilent Technologies, Inc., AstraZeneca PLC, Bayer AG, Bio-Rad Laboratories, Inc., BioCat GmbH by AddLife AB, Bioneer Corporation, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Cambridge Epigenetix Ltd., Chroma Medicine, Inc., Creative Biogene, Creative Diagnostics, Cusabio Technology LLC, Diagenode S.A. by Hologic, Inc., Elysium Health, Inc., EpiCypher, Inc., Epigenic Therapeutics, EpiGentek Group Inc., Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fios Genomics Ltd., FOXO Technologies Inc., GenomeScan, GenScript Biotech Corporation, Gilead Sciences, Inc., Illumina, Inc., Integrated DNA Technologies, Inc. by Danaher Corporation, Ipsen, Lonza Group Ltd., Merck KGaA, MorphoSys AG, New England Biolabs, Inc., Novogene Co, Ltd., Omega Therapeutics, Inc., Pacific Biosciences of California, Inc, PerkinElmer, Inc., Promega Corporation, ProteoGenix SAS, Qiagen N.V., Sound Agriculture Company, STORM Therapeutics LTD, Takara Holdings Inc., Thermo Fisher Scientific Inc., Twist Bioscience Corporation, Watchmaker Genomics, Inc., Zenith Epigenetics Ltd., and Zymo Research Corporation.

Market Segmentation & Coverage

This research report categorizes the Epigenetics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Enzymes
  - DNA-Modifying Enzymes
  - Protein-Modifying Enzymes

Instruments & Accessories
Reagents & Kits
- 5-hmC & 5-mC Analysis Kit
- Antibodies
- Bisulfite Conversion Kits
- ChiP-seq Kits
- Histones
- Whole Genome Amplification Kits

Service
Software

Technique
- Mass Spectrometry
- Next-Generation Sequencing
- Polymerase Chain Reaction & quantitative Polymerase Chain Reaction
- Sonication

Methods
- DNA Methylation
- Histone Modifications

Application
- Cardiovascular Diseases
- Developmental Biology
- Immunology
- Metabolic Diseases
- Oncology

End User
- Academic & Research Institutes
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Epigenetics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Epigenetics Market?

3. What are the technology trends and regulatory frameworks in the Epigenetics Market?

4. What is the market share of the leading vendors in the Epigenetics Market?

5. Which modes and strategic moves are suitable for entering the Epigenetics Market?

Product Code: MRR-0D217D5ADE3D

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Significant growth in the prevalence of chronic and genetic disorders worldwide
  - 5.1.1.2. Favorable governmental initiatives and investments in drug discovery and development
  - 5.1.1.3. Growing inclination toward personalized medicines
- 5.1.2. Restraints
  - 5.1.2.1. High cost of development of epigenetics technologies
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research and development activities for the advancement of epigenetics
  - 5.1.3.2. Expanding the application of epigenetics in non-oncology fields
- 5.1.4. Challenges
  - 5.1.4.1. Lack of awareness and limited application of epigenetics
5.2. Market Segmentation Analysis
- 5.2.1. Product: Increasing usage of reagents & kits for epigenetic research
- 5.2.2. Technique: Expanding adoption of next-generation sequencing for genome-wide methylation profiling
- 5.2.3. Methods: Rising utilization of DNA methylation for X-chromosome inactivation
- 5.2.4. Application: Increasing application of epigenetic tools in oncology
- 5.2.5. End-User: Growing need for epigenetic tools from academic & research institutes
5.3. Market Trend Analysis
- 5.3.1. Continuous epigenetics research for clinical and agricultural applications and technological advancements with a presence of major players in the Americas region
- 5.3.2. Increasing research and development activities coupled with growing geriatric population in the APAC region
- 5.3.3. Advanced healthcare infrastructure and strong epigenetics research activities associated with environment and agricultural applications in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Epigenetics Market, by Product

6.1. Introduction
6.2. Enzymes
6.3. Instruments & Accessories
6.4. Reagents & Kits
6.5. Service
6.6. Software

7. Epigenetics Market, by Technique

7.1. Introduction
7.2. Mass Spectrometry
7.3. Next-Generation Sequencing
7.4. Polymerase Chain Reaction & quantitative Polymerase Chain Reaction
7.5. Sonication

8. Epigenetics Market, by Methods

8.1. Introduction
8.2. DNA Methylation
8.3. Histone Modifications

9. Epigenetics Market, by Application

9.1. Introduction
9.2. Cardiovascular Diseases
9.3. Developmental Biology
9.4. Immunology
9.5. Metabolic Diseases
9.6. Oncology

10. Epigenetics Market, by End User

10.1. Introduction
10.2. Academic & Research Institutes
10.3. Contract Research Organizations
10.4. Pharmaceutical & Biotechnology Companies

11. Americas Epigenetics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Epigenetics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Epigenetics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Zenith and Cencora Partner to Expedite ZEN-3694 Programme
- 14.3.2. FOXO, DataRobot Partner for AI-Based Epigenetic Biomarker Research
- 14.3.3. Zymo Research and Opentrons Partner to Automate Novel Cell-Free DNA Isolation Chemistry
- 14.3.4. MSU biochemist Receives USD 2.8 million NIH Grant For Epigenetic Research on Autism Spectrum Disorder
- 14.3.5. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- 14.3.6. AstraZeneca Advances its Pipeline and Highlights Progress in Immuno-Oncology, ADCs, Cell Therapy and Epigenetics At AACR
- 14.3.7. Biomodal Releases Genetics And Epigenetics Solution
- 14.3.8. Chroma Medicine Raises Stakes in Epigenetic Editing
- 14.3.9. Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
- 14.3.10. Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio